You've probably seen the headlines about Foundayo, Eli Lilly's brand-new weight-loss pill. It got FDA approved back in April, and people are already asking me if it's "the shot, but in pill form." To be candid, I did not know too much about Foundayo until a client asked me about it a few weeks back. Now, with more asking me about it, I decided to do some research. Let's break down what it actually is, how it stacks up against Zepbound and Wegovy, and who it might actually make sense for. 🧬 WHAT IS IT, REALLY? Foundayo (generic name orforglipron) works on the same hormone pathway as Ozempic and Wegovy — it's called GLP-1. That hormone tells your brain "you're full" and slows down digestion, so cravings and portion sizes naturally shrink. The big difference: it's a pill you swallow once a day, not a weekly shot. 💊 WHY THIS ONE'S DIFFERENT - **No needles.** Straight up, it's a tablet. - **No fasting rules.** Take it any time of day, with or without food — unlike the other GLP-1 pill (Rybelsus), which makes you take it on an empty stomach first thing in the morning and wait 30 minutes to eat. - **Simple dosing.** Starts at a tiny 0.8 mg dose and moves up roughly once a month, up to 17.2 mg. 📊 WHAT THE RESEARCH SHOWED - People on the top dose lost about **27 lbs** on average (roughly 12% of body weight) over 72 weeks. - Compare that to Zepbound and Wegovy, which showed **15-22%** body weight loss in their own trials. Foundayo isn't as strong — it only targets GLP-1, while Zepbound also hits a second hormone (GIP) that adds extra punch. - Bonus: waist size, blood pressure, and cholesterol all improved too, not just the scale. ⚠️ SIDE EFFECTS TO KNOW Same GI stuff you'd expect from this drug class — nausea, constipation, diarrhea — most common while the dose is still climbing, and it tends to settle down over time. Same warnings as the shots too (thyroid, pancreas, gallbladder), so it's a conversation for your doctor, not a decision to make solo. 💡 WHERE THIS FITS INTO THE PLAN